Molnumize 200mg Capsule is a prescription-only medication containing molnupiravir, a direct-acting antiviral agent. Indicated for the treatment of mild to moderate COVID-19 in adults who are at high risk for progressing to severe COVID-19 or hospitalization. Molnumize is a single-dose oral therapy that inhibits the replication of SARS-CoV-2, thereby reducing the viral load and mitigating the severity of symptoms. The medication is contraindicated in patients with severe renal impairment or hypersensitivity to molnupiravir. Common adverse reactions include nausea, diarrhea, and headache. Molnumize has not been studied in pediatric patients, pregnant women, or breastfeeding individuals, and its use in these populations is not recommended. Patients should be advised to seek medical attention if they experience symptoms such as difficulty breathing, chest pain, or severe headache. Molnumize is a valuable addition to the armamentarium of COVID-19 treatments, offering a convenient and effective option for high-risk patients.

Dosage & How to Use